505 related articles for article (PubMed ID: 31771653)
21. A Risk Model Based on Immune-Related Genes Predicts Prognosis and Characterizes the Immune Landscape in Esophageal Cancer.
Xie Y; Fu R; Xiao Z; Li G
Pathol Oncol Res; 2022; 28():1610030. PubMed ID: 35356506
[TBL] [Abstract][Full Text] [Related]
22. Sex disparities revealed by single-cell and bulk sequencing and their impacts on the efficacy of immunotherapy in esophageal cancer.
Yan H; Huang J; Li Y; Zhao B
Biol Sex Differ; 2024 Mar; 15(1):22. PubMed ID: 38491510
[TBL] [Abstract][Full Text] [Related]
23. Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer.
Park R; Williamson S; Kasi A; Saeed A
Anticancer Res; 2018 Oct; 38(10):5569-5580. PubMed ID: 30275174
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy employing dendritic cell vaccination for patients with advanced or relapsed esophageal cancer.
Ogasawara M; Miyashita M; Yamagishi Y; Ota S
Ther Apher Dial; 2020 Oct; 24(5):482-491. PubMed ID: 32524770
[TBL] [Abstract][Full Text] [Related]
25. Roles of regulatory T cells in cancer immunity.
Takeuchi Y; Nishikawa H
Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy for cancer treatment.
Donátová K; Nováková E; Šupolíková M
Klin Onkol; 2022; 35(4):284-289. PubMed ID: 35989085
[TBL] [Abstract][Full Text] [Related]
27. Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment.
Li R; Huang B; Tian H; Sun Z
Front Oncol; 2022; 12():1096717. PubMed ID: 36698392
[TBL] [Abstract][Full Text] [Related]
28. Development and validation of a prognostic model for esophageal carcinoma based on immune microenvironment using system bioinformatics.
Fu C; Feng S; Wang S; Su X
Cancer Med; 2023 Jan; 12(2):2089-2103. PubMed ID: 35771026
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic strategies for gastric cancer targeting immune cells: Future directions.
Zhao Y; Bai Y; Shen M; Li Y
Front Immunol; 2022; 13():992762. PubMed ID: 36225938
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines.
Sanchez K; Page D; McArthur HL
Curr Probl Cancer; 2016; 40(2-4):151-162. PubMed ID: 27855963
[TBL] [Abstract][Full Text] [Related]
31. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
32. Investigation on the regulatory T cells signature and relevant Foxp3/STAT3 axis in esophageal cancer.
Yang L; Zhao Q; Wang X; Pilapong C; Li Y; Zou J; Jin J; Rong J
Cancer Med; 2023 Feb; 12(4):4993-5008. PubMed ID: 36226375
[TBL] [Abstract][Full Text] [Related]
33. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
34. Immune responses in patients with esophageal cancer treated with SART1 peptide-pulsed dendritic cell vaccine.
Narita M; Kanda T; Abe T; Uchiyama T; Iwafuchi M; Zheng Z; Liu A; Kaifu T; Kosugi S; Minagawa M; Itoh K; Takahashi M
Int J Oncol; 2015 Apr; 46(4):1699-709. PubMed ID: 25625346
[TBL] [Abstract][Full Text] [Related]
35. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant immunotherapy for resectable esophageal cancer: A review.
Li Q; Liu T; Ding Z
Front Immunol; 2022; 13():1051841. PubMed ID: 36569908
[TBL] [Abstract][Full Text] [Related]
37. Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy.
Su L; Hao Y; Li R; Pan W; Ma X; Weng J; Min Y
Acta Biomater; 2022 Dec; 154():401-411. PubMed ID: 36241013
[TBL] [Abstract][Full Text] [Related]
38. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis.
Yang H; Zhang Q; Xu M; Wang L; Chen X; Feng Y; Li Y; Zhang X; Cui W; Jia X
Mol Cancer; 2020 Feb; 19(1):41. PubMed ID: 32103760
[TBL] [Abstract][Full Text] [Related]
39. Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer.
Zheng Y; Fu Y; Wang PP; Ding ZY
Dis Markers; 2022; 2022():8270305. PubMed ID: 35211210
[TBL] [Abstract][Full Text] [Related]
40. Spatial Distribution and Predictive Significance of Dendritic Cells and Macrophages in Esophageal Cancer Treated With Combined Chemoradiotherapy and PD-1 Blockade.
Ma X; Guo Z; Wei X; Zhao G; Han D; Zhang T; Chen X; Cao F; Dong J; Zhao L; Yuan Z; Wang P; Pang Q; Yan C; Zhang W
Front Immunol; 2021; 12():786429. PubMed ID: 35046943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]